Boxer Capital Management, LLC - 18 Oct 2024 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Other*
Signature
By: /s/ Aaron I. Davis, Managing Member, Boxer Capital Management, LLC
Issuer symbol
TYRA
Transactions as of
18 Oct 2024
Net transactions value
$0
Form type
4
Filing time
22 Oct 2024, 20:49:28 UTC
Previous filing
22 Oct 2024
Next filing
23 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Disposed to Issuer -2,000,000 -31% 4,448,359 18 Oct 2024 See footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Pre-Funded Warrant (right to purchase) Award +2,000,000 +284% 2,705,280 18 Oct 2024 Common Stock 2,000,000 $0.001000 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Boxer Capital Management, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On October 18, 2024, Boxer Capital, LLC ("Boxer") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the "Pre-Funded Warrant"). The Pre-Funded Warrant was issued on October 22, 2024.
F2 These securities are beneficially owned indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of Boxer. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F3 The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. A holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Remarks:

The Reporting Person is a member of a group that formerly beneficially owned more than 10% of the outstanding shares of the Issuer's Common Stock.